Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Dermatologic 1CNS 1

Conditions

Sarcoma 3Neoplasms 3Sarcoma, Ewing 2Rhabdomyosarcoma 2Osteosarcoma 2Neuroblastoma 2Lung Neoplasms 2Breast Neoplasms 2Wilms Tumor 1Urinary Bladder Neoplasms 1Stomach Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms, Germ Cell and Embryonal 1Neoplasm Metastasis 1Melanoma 1Lymphoma, Non-Hodgkin 1Leukemia-Lymphoma, Adult T-Cell 1Kidney Neoplasms 1Histiocytoma 1Hereditary Sensory and Autonomic Neuropathies 1Hepatoblastoma 1Gliosarcoma 1Glioma 1Glioblastoma 1Fibrosarcoma 1Esophageal Neoplasms 1Dysgerminoma 1Dermatofibrosarcoma 1

Interventions

Trabectedin 1Topotecan 1Thiotepa 1Nivolumab 1Ifosfamide 1Filgrastim 1Cyproheptadine 1Carboplatin 1Albumin-Bound Paclitaxel 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Fibrosarcoma × Albumin-Bound Paclitaxel × CNS × Clear all
NCT01962103 2019-12-27

Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors

Celgene

Phase 1/2 Completed
107 enrolled 42 charts
CNSDermatologicSarcoma

Fibrosarcoma, Melanoma, Neoplasms, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Dermatofibrosarcoma, Histiocytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡